FUNDAMENTALS · Fundamentals · NL Healthcare

Pharming Group (PHAR) Fundamentals 2026 — P/E 66.8x, Revenue Analysis | SniperIQ

Pharming Group (PHAR) is a NL-listed Healthcare company in Biotechnology with a market capitalization of $943M, trading at

3.35 on the NASDAQ. This SniperIQ fundamentals page covers Pharming Group's valuation (P/E 66.8x, P/B 3.6x), profitability (net margin 3.4%), revenue (
76M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$943M
P/E (TTM)66.8x
Net Margin3.4%
Revenue (FY25)
76M

Full research coverage

Frequently Asked Questions

What is Pharming Group's market cap?

Pharming Group (PHAR) has a market capitalization of approximately $943M, trading at

3.35 on the NASDAQ. Market cap moves with the live share price.

What is Pharming Group's P/E ratio?

Pharming Group's trailing twelve-month P/E ratio is 66.8x, with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Pharming Group?

Pharming Group runs a net profit margin of 3.4%, a gross margin of 88.1%, and an operating margin of 6.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Pharming Group generate?

Pharming Group reported revenue of

76M for fiscal year 2025, with net income of
M and earnings per share (EPS) of 0.04. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Pharming Group pay a dividend?

Pharming Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Pharming Group financially healthy?

Pharming Group carries a debt-to-equity ratio of 0.43x and a current ratio of 2.63x, with a market beta of 0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Pharming Group a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pharming Group (PHAR) the key facts are: market cap $943M, P/E 66.8x, revenue

76M, 52-week range 9.535-21.34. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Pharming Group's full fundamentals live

Get Pharming Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.